Azenta, Inc. today announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics and a recognized leader in the biotechnology and pharmaceutical industries, has been elected to its Board ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.

Chronic Pain, that persists beyond the usual recovery period or occurs along with a chronic <a target=_blank href= ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

Healthcare stocks have been under the weather for the past few years, underperforming the broader market’s rally despite ...

WELLS, Maine — Wells High School has announced its first trimester honor roll for the 2024-25 school year.

Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued to clients and investors on ...

The leading Crohn's Disease companies such as Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.